Evaluation of matrix metalloproteinases in serum of patients with amyotrophic lateral sclerosis with pattern

B Sokolowska1, A Jozwik, I Niebroj-Dobosz

  • 1Department of Respiratory Research, Medical Research Center, Polish Academy of Sciences, Warsaw, Poland. sokolowskab@cmdik.pan.pl

Insights

Matrix metalloproteinases (MMPs) may help diagnose and track ALS progression. Pattern recognition methods show promise for identifying MMP-2 as a key biomarker in amyotrophic lateral sclerosis (ALS) patients.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Computational Biology

Background:

  • Matrix metalloproteinases (MMPs) are enzymes implicated in neurological diseases like ALS.
  • Understanding MMPs' role in ALS pathogenesis is crucial for developing diagnostic tools.

Purpose of the Study:

  • To apply pattern recognition methods for assessing MMPs in ALS patient serum.
  • To identify potential MMP biomarkers for ALS diagnosis and progression monitoring.

Main Methods:

  • Serum samples from 30 ALS patients (mild and severe subgroups) and 15 healthy controls were analyzed.
  • Levels of MT-MMP-1, MMP-2, and MMP-9 were quantified.
  • Standard, parallel, and hierarchical classifiers were used for pattern recognition analysis.

Main Results:

  • MMP-2 in serum emerged as a significant marker for evaluating ALS progression.
  • The combination of MT-MMP-1 and MMP-9 showed potential in distinguishing ALS patients from healthy individuals.
  • Pattern recognition classifiers, including k-NN based methods, yielded comparable error rates.

Conclusions:

  • Pattern recognition techniques are valuable for evaluating MMPs as biomarkers in neurodegenerative diseases like ALS.
  • MMP-2 and the {MT-MMP-1, MMP-9} set show potential for clinical application in ALS management.